120 related articles for article (PubMed ID: 33392702)
1. A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma.
Oliva S; De Paoli L; Ruggeri M; Caltagirone S; Troia R; Oddolo D; D'Agostino M; Gilestro M; Mina R; Saraci E; Margiotta Casaluci G; Genuardi E; Bringhen S; Boccadoro M; Omedé P
Ann Hematol; 2021 Feb; 100(2):437-443. PubMed ID: 33392702
[TBL] [Abstract][Full Text] [Related]
2. Cytogenetic Profile in Monoclonal Gammopathy of Undetermined Significance, Smoldering and Symptomatic Multiple Myeloma: A Study of 1087 Patients with Highly Purified Plasma Cells.
Tang G; Wu Y; Lin P; Toruner GA; Hu S; Li S; Qazilbash MH; Orlowski RZ; Ye C; Xu J; Nahmod KA; Medeiros LJ; Tang Z
Cancers (Basel); 2023 Dec; 15(23):. PubMed ID: 38067393
[TBL] [Abstract][Full Text] [Related]
3. Stromal alterations in patients with monoclonal gammopathy of undetermined significance, smoldering myeloma, and multiple myeloma.
Bogun L; Koch A; Scherer B; Fenk R; Maus U; Bormann F; Köhrer K; Petzsch P; Wachtmeister T; Zukovs R; Dietrich S; Haas R; Schroeder T; Jäger P; Geyh S
Blood Adv; 2024 May; 8(10):2575-2588. PubMed ID: 38241490
[TBL] [Abstract][Full Text] [Related]
4. Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma.
Goyal G; Rajkumar SV; Lacy MQ; Gertz MA; Buadi FK; Dispenzieri A; Hwa YL; Fonder AL; Hobbs MA; Hayman SR; Zeldenrust SR; Lust JA; Russell SJ; Leung N; Kapoor P; Go RS; Gonsalves WI; Kourelis TV; Warsame R; Kyle RA; Kumar SK
Leukemia; 2019 May; 33(5):1273-1277. PubMed ID: 30787429
[TBL] [Abstract][Full Text] [Related]
5. Determination of the target of monoclonal immunoglobulins: a novel diagnostic tool for individualized MGUS therapy, and prevention and therapy of smoldering and multiple myeloma.
Hermouet S; Bigot-Corbel E; Harb J
Front Immunol; 2023; 14():1253363. PubMed ID: 38022528
[TBL] [Abstract][Full Text] [Related]
6. Minor clone of del(17p) provides a reservoir for relapse in multiple myeloma.
Cui J; Lv R; Yu T; Yan W; Xu J; Fan H; Li L; Liu Y; Du C; Deng S; Sui W; Xu Y; Yi S; Zou D; Qiu L; An G
Haematologica; 2024 Feb; 109(2):591-603. PubMed ID: 37534514
[TBL] [Abstract][Full Text] [Related]
7. Advances in the molecular characterization of multiple myeloma and mechanism of therapeutic resistance.
Mejia Saldarriaga M; Darwiche W; Jayabalan D; Monge J; Rosenbaum C; Pearse RN; Niesvizky R; Bustoros M
Front Oncol; 2022; 12():1020011. PubMed ID: 36387095
[TBL] [Abstract][Full Text] [Related]
8. Fluorescence in situ hybridization reveals the evolutionary biology of minor clone of gain/amp(1q) in multiple myeloma.
Cui J; Liu Y; Lv R; Yan W; Xu J; Li L; Du C; Yu T; Zhang S; Deng S; Sui W; Hao M; Yi S; Zou D; Qiu L; Xu Y; An G
Leukemia; 2024 Jun; 38(6):1299-1306. PubMed ID: 38609496
[TBL] [Abstract][Full Text] [Related]
9. Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas.
Yadav U; Kumar SK; Baughn LB; Dispenzieri A; Greipp P; Ketterling R; Jevremovic D; Buadi FK; Dingli D; Lacy MQ; Fonseca R; Bergsagel PL; Ailawadhi S; Roy V; Parrondo R; Sher T; Hayman SR; Kapoor P; Leung N; Cook J; Binder M; Muchtar E; Warsame R; Kourelis TV; Go RS; Lin Y; Seth A; Lester SC; Breen WG; Kyle RA; Gertz MA; Rajkumar SV; Gonsalves WI
Blood; 2023 Nov; 142(22):1871-1878. PubMed ID: 37494698
[TBL] [Abstract][Full Text] [Related]
10. Isolation of circulating plasma cells from blood of patients diagnosed with clonal plasma cell disorders using cell selection microfluidics.
Kamande JW; Lindell MAM; Witek MA; Voorhees PM; Soper SA
Integr Biol (Camb); 2018 Feb; 10(2):82-91. PubMed ID: 29372735
[TBL] [Abstract][Full Text] [Related]
11. The progress in multiple myeloma.
Hatjiharissi P
Hell J Nucl Med; 2023; 26 Suppl():30-35. PubMed ID: 37658559
[TBL] [Abstract][Full Text] [Related]
12. Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression.
Bustoros M; Sklavenitis-Pistofidis R; Park J; Redd R; Zhitomirsky B; Dunford AJ; Salem K; Tai YT; Anand S; Mouhieddine TH; Chavda SJ; Boehner C; Elagina L; Neuse CJ; Cha J; Rahmat M; Taylor-Weiner A; Van Allen E; Kumar S; Kastritis E; Leshchiner I; Morgan EA; Laubach J; Casneuf T; Richardson P; Munshi NC; Anderson KC; Trippa L; Aguet F; Stewart C; Dimopoulos MA; Yong K; Bergsagel PL; Manier S; Getz G; Ghobrial IM
J Clin Oncol; 2020 Jul; 38(21):2380-2389. PubMed ID: 32442065
[TBL] [Abstract][Full Text] [Related]
13. Decreased neutrophil function in newly diagnosed multiple myeloma patients is restored with lenalidomide therapy.
Askman S; Westerlund J; Pettersson Å; Hellmark T; Johansson Å; Wichert S; Hansson M
Eur J Haematol; 2024 Jul; 113(1):72-81. PubMed ID: 38553844
[TBL] [Abstract][Full Text] [Related]
14. From Multiple Myeloma to Acute Myeloid Leukemia: A Case Report of a 61-year-old Woman after 8 Years of Chemotherapy and Immunotherapy.
Fu XH; Guan RY; Huang Z; Li Y; Lu G; Mou WW; Du J
Recent Pat Anticancer Drug Discov; 2024; 19(3):396-401. PubMed ID: 38214323
[TBL] [Abstract][Full Text] [Related]
15. In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present From Diagnosis in Tiny, Undetectable Subclonal Populations.
Lannes R; Samur M; Perrot A; Mazzotti C; Divoux M; Cazaubiel T; Leleu X; Schavgoulidze A; Chretien ML; Manier S; Adiko D; Orsini-Piocelle F; Lifermann F; Brechignac S; Gastaud L; Bouscary D; Macro M; Cleynen A; Mohty M; Munshi N; Corre J; Avet-Loiseau H
J Clin Oncol; 2023 Mar; 41(9):1695-1702. PubMed ID: 36343306
[TBL] [Abstract][Full Text] [Related]
16. The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression.
Medina-Herrera A; Vazquez I; Cuenca I; Rosa-Rosa JM; Ariceta B; Jimenez C; Fernandez-Mercado M; Larrayoz MJ; Gutierrez NC; Fernandez-Guijarro M; Gonzalez-Calle V; Rodriguez-Otero P; Oriol A; Rosiñol L; Alegre A; Escalante F; De La Rubia J; Teruel AI; De Arriba F; Hernandez MT; Lopez-Jimenez J; Ocio EM; Puig N; Paiva B; Lahuerta JJ; Bladé J; San Miguel JF; Mateos MV; Martinez-Lopez J; Calasanz MJ; Garcia-Sanz R;
Blood Cancer J; 2024 Apr; 14(1):74. PubMed ID: 38684670
[TBL] [Abstract][Full Text] [Related]
17. RAB22A as a predictor of exosome secretion in the progression and relapse of multiple myeloma.
Fan B; Wang L; Wang J
Aging (Albany NY); 2024 Mar; 16(5):4169-4190. PubMed ID: 38431306
[TBL] [Abstract][Full Text] [Related]
18. Dissecting molecular mechanisms of immune microenvironment dysfunction in multiple myeloma and precursor conditions.
Moscvin M; Evans B; Bianchi G
J Cancer Metastasis Treat; 2023; 9():. PubMed ID: 38213954
[TBL] [Abstract][Full Text] [Related]
19. Genomic patterns of progression in smoldering multiple myeloma.
Bolli N; Maura F; Minvielle S; Gloznik D; Szalat R; Fullam A; Martincorena I; Dawson KJ; Samur MK; Zamora J; Tarpey P; Davies H; Fulciniti M; Shammas MA; Tai YT; Magrangeas F; Moreau P; Corradini P; Anderson K; Alexandrov L; Wedge DC; Avet-Loiseau H; Campbell P; Munshi N
Nat Commun; 2018 Aug; 9(1):3363. PubMed ID: 30135448
[TBL] [Abstract][Full Text] [Related]
20. Cytogenetic abnormalities correlate with clinico-biological characteristics in 30 Moroccan multiple myeloma patients.
Hamdaoui H; Nouadi B; Benlarroubia O; Chbel F; Saadoune C; Bennis F; Lamzouri A; Chegdani F
Leuk Res Rep; 2023; 20():100392. PubMed ID: 38035181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
